Phase 3 trial

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.

Pfizer shares rise on Phase 3 prostate cancer trial win and Phase 2 breast cancer success, validating its oncology pipeline and signaling near-term regulatory catalysts.

Chemomab Therapeutics achieved FDA End-of-Phase 2 approval for nebokitug in PSC treatment, establishing streamlined regulatory pathway with promising Phase 2 data.

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.

Reviva Pharmaceuticals prices $10M offering at $1.50/share to fund brilaroxazine Phase 3 schizophrenia trial and operations.

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.

Rhythm Pharmaceuticals' setmelanotide fails EMANATE Phase 3 primary endpoints for rare genetic obesity, sending stock down 4.98%. Company pivots to next-generation MC4R agonists.

Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.

Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.

Moleculin Biotech releases CEO update on Phase 3 MIRACLE trial evaluating Annamycin for relapsed/refractory acute myeloid leukemia, with enrollment progressing on schedule.

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.

$VERX surges 6.3% after kidney drug povetacicept achieves Phase 3 trial success with 52% proteinuria reduction, positioning FDA approval by year-end.

Celcuity's gedatolisib achieved 76% risk reduction in advanced breast cancer with PIK3CA wild-type mutations; FDA Priority Review decision expected July 2026.

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.

Dianthus Therapeutics will present interim responder analysis from Phase 3 CAPTIVATE trial of claseprubart for CIDP treatment on March 9, 2026.

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.

Nxera Pharma seeks South Korean approval for insomnia drug daridorexant, already marketed globally, with expected 2027 regulatory decision.